Cannara Biotech Inc. has seen some interesting movements and developments recently.
Cannara Biotech Inc. (LOVE.TO) is currently in the spotlight as it reports a modest increase in stock performance over the past week. The latest updates from the company reflect its ongoing efforts to strengthen its market position and expand its operations in the cannabis sector.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeMarket cap
$183.73M
P/E
16.9x
52W high
$2.05
52W low
$1.55
1W change
+1.08%
Beta
0.35
Analyst Price Targets
Based on analyst covering LOVE
Wall Street analysts forecast LOVE stock price to rise 79.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.38
+79.5% Upside
Current Price
C$1.88
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
42.0%
Annualized
90-Day Vol
36.1%
Annualized
Trend (90d)
+30.1%
Annualized drift
90d Mean
C$2.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.95 | C$1.69 – C$2.25 |
| 60 trading days | C$2.02 | C$1.65 – C$2.48 |
| 90 trading days | C$2.09 | C$1.63 – C$2.69 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Cannara's recent achievements, including record revenues and strategic acquisitions, may bolster investor confidence. However, the stock's relatively low beta suggests less volatility compared to the broader market, which could appeal to conservative investors.
Cannara Reports Q3 Revenues of $31.8 Million
The company achieved an adjusted EBITDA of $8.5 million, showcasing its profitability amidst expanding operations.
Bull case
Cannara's strong financial performance in Q3, with net revenues of $31.8 million, indicates a promising growth trajectory. The acquisition of Medican Organic Inc. enhances its market presence and product offerings, which could lead to further revenue growth.
Bear case
Despite these positive results, Cannara faces challenges in a competitive cannabis market, including regulatory hurdles and shifting market dynamics. Additionally, the stock's modest trading volume compared to its average might suggest lower investor interest.
Recent Price Action
Cannara Biotech Inc. (LOVE.TO) has experienced a slight increase in its stock price, closing at C$1.86. Over the last week, the stock rose by 1.08%, and it has shown a year-to-date gain of 2.17%. The stock's performance reflects a steady upward trend, particularly in the context of its recent financial announcements.
Advertisement
Company News and Catalysts
Recently, Cannara reported record Q3 revenues of $31.8 million, accompanied by an adjusted EBITDA of $8.5 million. This financial success is attributed to expanded national distribution and accelerated capacity expansion. Additionally, the company completed the acquisition of Medican Organic Inc. for $2.8 million, further solidifying its position in the cannabis market. These developments have contributed to a positive outlook among analysts, with an average target price of C$3.38, suggesting a potential upside of 81.5%.
Technical Picture
The technical indicators for Cannara show that the stock is currently trading above its 50-day moving average of C$1.75 and its 200-day moving average of C$1.77, indicating a bullish trend. The stock has a 52-week range of C$1.55 to C$2.05, positioning it at approximately 62% of its range. With a beta of 0.35, Cannara exhibits lower volatility compared to the broader market. The latest trading volume of 58,415 shares is slightly above its 20-day average volume of 52,729 shares, suggesting a stable interest in the stock.
Insider Activity
There are no recent insider activity reports available for Cannara Biotech Inc. This lack of insider transactions may indicate stability in management or a focus on long-term growth strategies.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
